Drugs / NEO-PV-01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03166254 | Apr 2019 → Jun 2022 | non-small cell lung carcinoma, small cell lung carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03597282 | Oct 2018 → May 2020 | metastatic melanoma | BioNTech US Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03380871 | May 2018 → Oct 2019 | non-small cell lung carcinoma | BioNTech US Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02897765 | Oct 2016 → Feb 2019 | bladder transitional cell carcinoma, melanoma, non-small cell lung carcinoma, skin cancer | BioNTech US Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEO-PV-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03380871 ↗ |
| Modality | Vaccine | “A new, investigational, personal cancer vaccine called "NEO-PV-01"” NCT02897765 ↗ |
| Route | Subcutaneous | “NEO-PV-01 + adjuvant administered subcutaneously” NCT02897765 ↗ |